Involvement of B3GALNT2 overexpression in the cell growth of breast cancer

Matsuo,Taisuke; Komatsu,Masato; Yoshimaru,Tetsuro; Kiyotani,Kazuma; Miyoshi,Yasuo; Sasa,Mitsunori; Katagiri,Toyomasa

doi:10.3892/ijo.2013.2187

Involvement of B3GALNT2 overexpression in the cell growth of breast cancer

Authors:
- Taisuke Matsuo
- Masato Komatsu
- Tetsuro Yoshimaru
- Kazuma Kiyotani
- Yasuo Miyoshi
- Mitsunori Sasa
- Toyomasa Katagiri
View Affiliations

Affiliations: Division of Genome Medicine, Institute for Genome Research, The University of Tokushima, Tokushima 770-8503, Japan, Department of Surgery, Division of Breast and Endocrine Surgery, Hyogo College of Medicine, Hyogo 663-8501, Japan, Department of Surgery, Tokushima Breast Care Clinic, Tokushima 770-0052, Japan
Published online on: November 27, 2013 https://doi.org/10.3892/ijo.2013.2187
Pages: 427-434

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A number of glycosyltransferases have been identified and biologically characterized in cancer cells, yet their exact pathophysiological functions are largely unknown. Here, we report the critical role of β1,3-N-acetylgalactosaminyltransferase II (B3GALNT2), which transfers N-acetylgalactosamine (GalNAc) in a β1,3 linkage to N-acetylglucosamine, in the growth of breast cancer cells. Comprehensive transcriptomics, quantitative PCR and northern blot analyses indicated this molecule to be exclusively upregulated in the majority of breast cancers. Knockdown of B3GALNT2 expression by small interfering RNA attenuated cell growth and induced apoptosis in breast cancer cells. Overexpression of B3GALNT2 in HEK293T cells prompted secretion of the gene product into the culture medium, suggesting that B3GALNT2 is potentially a secreted protein. Furthermore, we demonstrated that B3GALNT2 is N-glycosylated on both Asn-116 and Asn-174 and that this modification is necessary for its secretion in breast cancer cells. Our findings suggest that this molecule represents a promising candidate for the development of a novel therapeutic targeting drug and a potential diagnostic tumor marker for patients with breast cancer, especially TNBC.

View Figures

View References

1.	Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T and Thun MJ: Cancer Statistics, 2008. CA Cancer J Clin. 58:71–96. 2008. View Article : Google Scholar
2.	Di Cosmo S and Baselga J: Management breast cancer with targeted agents: Importance of heterogeneity. Nat Rev Clin Oncol. 7:139–147. 2010.PubMed/NCBI
3.	Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD and Feuer EJ: Cancer Intervention and Surveillance Modeling Network (CISNET) Collaborators: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 353:1784–1792. 2005. View Article : Google Scholar : PubMed/NCBI
4.	Early Breast Cancer Trialists’ Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 365:1687–1717. 2005.PubMed/NCBI
5.	Adamo V, Iorfida M, Montalto E, Festa V, Garipoli C, Scimone A, Zanghì M and Caristi N: Overview and new strategies in metastatic breast cancer (MBC) for treatment of tamoxifen-resistant patients. Ann Oncol. 18:53–57. 2007. View Article : Google Scholar : PubMed/NCBI
6.	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
7.	Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to neoadjuvant therapy and longterm survival in patients with triple-negative breast cancer. J Clin Oncol. 26:1275–1281. 2008. View Article : Google Scholar : PubMed/NCBI
8.	Petricoin EF III, Hackett JL, Lesko LJ, Puri RK, Gutman SI, Chumakov K, Woodcock J, Feigal DW Jr, Zoon KC and Sistare FD: Medical applications of microarray technologies: a regulatory science perspective. Nat Genet. 32:474–479. 2002. View Article : Google Scholar : PubMed/NCBI
9.	Nishidate T, Katagiri T, Lin ML, Mano Y, Miki Y, Kasumi F, Yoshimoto M, Tsunoda T, Hirata K and Nakamura Y: Genome-wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis. Int J Oncol. 25:797–819. 2004.
10.	Komatsu M, Yoshimaru T, Matsuo T, Kiyotani K, Miyoshi Y, Tanahashi T, Rokutan K, Yamaguchi R, Saito A, Imoto S, Miyano S, Nakamura Y, Sasa M, Shimada M and Katagiri T: Molecular features of triple negative breast cancer cells by genome-wide gene expression profiling analysis. Int J Oncol. 42:478–506. 2013.PubMed/NCBI
11.	Hiruma T, Togayachi A, Okamura K, Sato T, Kikuchi N, Kwon YD, Nakamura A, Fujimura K, Gotoh M, Tachibana K, Ishizuka Y, Noce T, Nakanishi H and Narimatsu H: A novel human beta1,3-N-acetylgalactosaminyltransferase that synthesizes a unique carbohydrate structure, GalNAcbeta1-3GlcNAc. J Biol Chem. 279:14087–14095. 2004. View Article : Google Scholar : PubMed/NCBI
12.	Hart GW and Copeland RJ: Glycomics hits the big time. Cell. 143:672–676. 2010. View Article : Google Scholar : PubMed/NCBI
13.	Fuster MM and Esko JD: The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer. 5:526–542. 2005. View Article : Google Scholar : PubMed/NCBI
14.	Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T: Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 70:2759–2769. 2010. View Article : Google Scholar : PubMed/NCBI
15.	Park JH, Katagiri T, Chung S, Kijima K and Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 13:320–326. 2011.PubMed/NCBI
16.	Potapenko IO, Haakensen VD, Lüders T, Helland A, Bukholm I, Sørlie T, Kristensen VN, Lingjaerde OC and Børresen-Dale AL: Glycan gene expression signatures in normal and malignant breast tissue; possible role in diagnosis and progression. Mol Oncol. 4:98–118. 2010. View Article : Google Scholar : PubMed/NCBI
17.	Park JH, Lin ML, Nishidate T, Nakamura Y and Katagiri T: PDZ-binding kinase/T-LAK cell-originated protein kinase, a putative cancer/testis antigen with an oncogenic activity in breast cancer. Cancer Res. 66:9186–9195. 2006. View Article : Google Scholar : PubMed/NCBI
18.	Kim JW, Akiyama M, Park JH, Lin ML, Shimo A, Ueki T, Daigo Y, Tsunoda T, Nishidate T, Nakamura Y and Katagiri T: Activation of an estrogen/estrogen receptor signaling by BIG3 through its inhibitory effect on nuclear transport of PHB2/REA in breast cancer. Cancer Sci. 100:1468–1478. 2009. View Article : Google Scholar : PubMed/NCBI
19.	Shimo A, Nishidate T, Ohta T, Fukuda M, Nakamura Y and Katagiri T: Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Sci. 98:174–181. 2007. View Article : Google Scholar : PubMed/NCBI
20.	Nogueira E, Fidalgo M, Molnar A, Kyriakis J, Force T, Zalvide J and Pombo CM: SOK1 translocates from the Golgi to the nucleus upon chemical anoxia and induces apoptotic cell death. J Biol Chem. 283:16248–16258. 2008. View Article : Google Scholar : PubMed/NCBI
21.	Paulson JC and Colley KJ: Glycosyltransferases. Structure, localization, and control of cell type-specific glycosylation. J Biol Chem. 264:17615–17618. 1989.PubMed/NCBI
22.	El-Battari A, Prorok M, Angata K, Mathieu S, Zerfaoui M, Ong E, Suzuki M, Lombardo D and Fukuda M: Different glycosyltransferases are differentially processed for secretion, dimerization, and autoglycosylation. Glycobiology. 13:941–953. 2003. View Article : Google Scholar : PubMed/NCBI
23.	Kato T, Suzuki M, Murata T and Park EY: The effects of N-glycosylation sites and the N-terminal region on the biological function of beta1,3-N-acetylglucosaminyltransferase 2 and its secretion. Biochem Biophys Res Commun. 329:699–705. 2005. View Article : Google Scholar : PubMed/NCBI
24.	Brockhausen I: Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys Acta. 1473:67–95. 1999. View Article : Google Scholar : PubMed/NCBI
25.	Yoshida-Moriguchi T, Yu L, Stalnaker SH, Davis S, Kunz S, Madson M, Oldstone MB, Schachter H, Wells L and Campbell KP: O-mannosyl phosphorylation of alpha-dystroglycan is required for laminin binding. Science. 327:88–92. 2010. View Article : Google Scholar : PubMed/NCBI
26.	Stevens E, Carss KJ, Cirak S, Foley AR, Torelli S, Willer T, Tambunan DE, Yau S, Brodd L, Sewry CA, Feng L, Haliloglu G, Orhan D, Dobyns WB, Enns GM, Manning M, Krause A, Salih MA, Walsh CA, Hurles M, Campbell KP, Manzini MC; UK10K Consortium; Stemple D, Lin YY and Muntoni F: Mutations in B3GALNT2 cause congenital muscular dystrophy and hypoglycosylation of α-dystroglycan. Am J Hum Genet. 92:354–365. 2013.PubMed/NCBI
27.	Sgambato A, Migaldi M, Montanari M, Camerini A, Brancaccio A, Rossi G, Cangiano R, Losasso C, Capelli G, Trentini GP and Cittadini A: Dystroglycan expression is frequently reduced in human breast and colon cancers and is associated with tumor progression. Am J Pathol. 162:849–860. 2003. View Article : Google Scholar : PubMed/NCBI
28.	Saito T, Miyoshi E, Sasai K, Nakano N, Eguchi H, Honke K and Taniguchi N: A secreted type of β1,6-N-acetylglucosaminyltransferase-V (GnT-V) induces tumor angiogenesis without mediation of glycosylation. A novel function of GnT-V distinct from the original glycosyltransferase activity. J Biol Chem. 277:17002–17008. 2002.
29.	Toki D, Sarkar M, Yip B, Reck F, Joziasse D, Fukuda M, Schachter H and Brockhausen I: Expression of stable human O-glycan core 2 beta-1,6-N-acetylglucosaminyltransferase in Sf9 insect cells. Biochem J. 325:63–69. 1997.PubMed/NCBI
30.	Barbier O, Girard C, Breton R, Bélanger A and Hum DW: N-glycosylation and residue 96 are involved in the functional properties of UDP-glucuronosyltransferase enzymes. Biochemistry. 39:11540–11552. 2000. View Article : Google Scholar : PubMed/NCBI
31.	Christensen LL, Bross P and Ørntoft TF: Glycosylation of the N-terminal potential N-glycosylation sites in the human alpha1,3-fucosyltransferase V and -VI (hFucTV and -VI). Glycoconj J. 17:859–865. 2000. View Article : Google Scholar : PubMed/NCBI